{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-unidentified-cause/goals-outcome-measures/audit-criteria/","result":{"pageContext":{"chapter":{"id":"54d592f8-f244-5cc8-aed5-81cb136af042","slug":"audit-criteria","fullItemName":"Audit criteria","depth":2,"htmlHeader":"<!-- begin field 470c6fef-2c08-426f-bf4f-2bd433b6620b --><h2>Audit criteria</h2><!-- end field 470c6fef-2c08-426f-bf4f-2bd433b6620b -->","summary":null,"htmlStringContent":"<!-- begin item 478bf9b0-c51c-4b8a-80d2-112a0fdcbca2 --><!-- begin field 1467306e-64d0-439b-8dff-8d1b94a58be4 --><p>The following National Institute of Health and Care Excellence (NICE) audit criteria are relevant for this CKS topic:</p><ul><li>Audit criterion 1. A 2-week washout period is left after proton pump inhibitor (PPI) use before testing for <em>Helicobacter pylori</em> (<em>H. pylori</em>) with a breath test or stool antigen test.</li><li>Audit criterion 2. Empirical full-dose proton pump inhibitor (PPI) therapy is offered for 4 weeks for people with dyspepsia.</li><li>Audit criterion 3. All people with dyspepsia are offered <em>H. pylori</em> 'test and treat'.</li><li>Audit criterion 4. If symptoms of dyspepsia or GORD return after initial care strategies, PPI therapy is stepped down to the lowest dose needed to control symptoms.</li><li>Audit criterion 5. H<sub>2</sub> receptor antagonist (H<sub>2</sub>RA) therapy is offered if there is an inadequate response to a PPI.</li></ul><p><em>H. pylori</em> testing</p><ul><li>1. <em>H. pylori</em> is tested for using a carbon-13 urea breath test or a stool antigen test or laboratory-based serology.</li><li>2. Re-testing for <em>H. pylori</em> is performed using a carbon-13 urea breath test.</li><li>3. Office-based serological tests are not used.</li></ul><p>First-line <em>H. pylori</em> treatment</p><ul><li>4. People who test positive for <em>H. pylori</em> are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>amoxicillin and</li><li>either clarithromycin or metronidazole.</li></ul></li><li>5. People who are allergic to penicillin are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>clarithromycin and</li><li>metronidazole.</li></ul></li><li>6. People who are allergic to penicillin and who have had previous exposure to clarithromycin are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>bismuth and</li><li>metronidazole and</li><li>tetracycline.</li></ul></li></ul><p>Second-line <em>H. pylori</em> treatment</p><ul><li>7. People who still have symptoms after first-line eradication treatment are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>amoxicillin and</li><li>either clarithromycin or metronidazole (whichever was not used first-line).</li></ul></li><li>8. People who have had previous exposure to clarithromycin and metronidazole are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and</li><li>amoxicillin and</li><li>a quinolone or tetracycline.</li></ul></li><li>9. People who are allergic to penicillin and have not had previous exposure to a quinolone are offered a 7-day, twice-daily course of treatment with:<ul><li>a PPI and </li><li>metronidazole and </li><li>levofloxacin.</li></ul></li><li>10. People who are allergic to penicillin and who have had previous exposure to a quinolone are offered:<ul><li>a PPI and</li><li>bismuth and</li><li>metronidazole and</li><li>tetracycline.</li></ul></li><li>11. If eradication of <em>H. pylori</em> is not successful with second-line treatment, advice is sought from a gastroenterologist.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-unidentified-cause/references/\">NICE, 2014</a>]</p><!-- end field 1467306e-64d0-439b-8dff-8d1b94a58be4 --><!-- end item 478bf9b0-c51c-4b8a-80d2-112a0fdcbca2 -->","topic":{"id":"f89632d0-8e52-59da-bd63-555a73aa134f","topicId":"ac596995-c452-4bf5-81bf-0aea66eca309","topicName":"Dyspepsia - unidentified cause","slug":"dyspepsia-unidentified-cause","lastRevised":"Last revised in October 2018","chapters":[{"id":"9fdd530d-f12b-5642-954b-6284524a3fdb","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"4ac2b712-5571-56ca-9ac4-25c9e354a821","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"16fcbe75-c057-5b25-8039-9145eb897f12","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"be6e1eb9-7eb4-54b8-980d-7a18a90127c3","slug":"changes","fullItemName":"Changes"},{"id":"8eb7dbc2-40da-5433-b290-44902a364d61","slug":"update","fullItemName":"Update"}]},{"id":"a44ffd66-34ee-565e-8b89-d09f62dd9656","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ad917944-2a8c-561c-ba7d-5e5c7ea860e4","slug":"goals","fullItemName":"Goals"},{"id":"cbb4bad0-1dbe-5c62-9adc-bb1a65fe6381","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"54d592f8-f244-5cc8-aed5-81cb136af042","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4ca8a0b2-46c5-52c2-a05d-1ae84806cefd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c5e33c66-dee5-57d8-9eff-828ad855e204","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"eff9b41a-cac2-5b9a-8614-2486d8206ffd","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"4dfc51d9-1416-5432-bc80-019f5708238c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec8766af-6b0a-5a4d-8897-2e3ba2af658d","slug":"definition","fullItemName":"Definition"},{"id":"e1cbef45-8ac7-5376-a1d2-c5d0a2cc924b","slug":"causes","fullItemName":"Causes"},{"id":"c7487dda-a4e1-5d9e-bc96-e583302af12c","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"0eb82dd3-e433-5b8e-a8d9-46987aab8940","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d2acef31-cf6d-5e3e-b2e0-99bc02684183","slug":"assessment","fullItemName":"Assessment"},{"id":"86ebd63c-3596-5ac0-9cd3-4a312bb2d7e4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"f244ecd9-294a-5fa3-9b22-a2e8f2ae408c","fullItemName":"Management","slug":"management","subChapters":[{"id":"bafb1a12-7cf3-5c6c-921a-03d86efd995d","slug":"dyspepsia-unidentified-cause","fullItemName":"Scenario: Dyspepsia - unidentified cause"}]},{"id":"b50160d9-c6d3-5b75-a3a3-9a743c039fb4","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2978bf31-384a-5964-bba7-5ca72e2a700a","slug":"proton-pump-inhibitors-ppis","fullItemName":"Proton pump inhibitors (PPIs)"},{"id":"a51b3918-0bed-5c45-887b-a5d3e5fd3031","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"8579e41d-876a-5f82-9cb8-04675dce1bb3","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"d41b619e-ef9e-59b6-876b-0b3d52f0884a","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"9ea259a4-6c7f-524f-8866-6164a9696c25","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"640d4b46-3f9c-5cef-aeda-9a374a03fae8","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"fe5b2b68-8d84-5867-bc39-c63cbcd815f8","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"0857fa25-e261-5ecd-b851-fbe52518072d","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"210b1a7b-a0e0-558a-acbe-539f538e840d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0e0cffca-8140-5660-bd87-d4288485522f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4726f06d-25b6-56d1-83c0-3d729c2bb571","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"301b4d9b-8d13-5cc1-8e9a-f8f68c4fa019","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5e963a22-e16a-5e4a-b7a9-072decaccaa1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1d047d4-3011-5ca0-955c-b366ab2a9fb4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"cd5de0cc-ba55-5ad9-b09b-3025cc68334c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc0ebb19-4869-5b31-8bcf-f0b6e5af54db","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"a44ffd66-34ee-565e-8b89-d09f62dd9656","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}